Atagabalin

Atagabalin
Clinical data
ATC code	none;
Identifiers
	IUPAC name [(3S,4S)-1-(aminomethyl)-3,4-dimethylcyclopentyl]acetic acid;
CAS Number	223445-75-8 ;
PubChem CID	9794485;
ChemSpider	7970252 ;
UNII	JT7957Q2FB;
ChEMBL	ChEMBL593430 ;
CompTox Dashboard (EPA)	DTXSID80944993 ;
Chemical and physical data
Formula	C10H19NO2
Molar mass	185.263 g/mol g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@H]1CC(C[C@@H]1C)(CC(=O)O)CN;
	InChI InChI=1S/C10H19NO2/c1-7-3-10(6-11,4-8(7)2)5-9(12)13/h7-8H,3-6,11H2,1-2H3,(H,12,13)/t7-,8-/m0/s1 ; Key:IUVMAUQEZFTTFB-YUMQZZPRSA-N ;
	(what is this?) (verify)

Atagabalin (PD-0200,390) is a drug developed by Pfizer and related to gabapentin, which similarly binds to the α₂δ calcium channels (1 and 2).^[1] It is under development as a treatment for insomnia.^[2]^[3]^[4]

References

^ Blakemore DC, Bryans JS, Carnell P, Carr CL, Chessum NE, Field MJ, Kinsella N, Osborne SA, Warren AN, Williams SC (January 2010). "Synthesis and in vivo evaluation of bicyclic gababutins". Bioorganic & Medicinal Chemistry Letters. 20 (2): 461–4. doi:10.1016/j.bmcl.2009.11.118. PMID 20005103.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Corrigan B, Feltner DE, Ouellet D, Werth JL, Moton AE, Gibson G (August 2009). "Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit". British Journal of Clinical Pharmacology. 68 (2): 174–80. doi:10.1111/j.1365-2125.2009.03444.x. PMC 2767279. PMID 19694735.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Quintero JE, Pomerleau F, Huettl P, Johnson KW, Offord J, Gerhardt GA (May 2011). "Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: Basic characterization and drug pharmacology". Brain Research. 1401: 1–9. doi:10.1016/j.brainres.2011.05.025. PMID 21664606.{{cite journal}}: CS1 maint: multiple names: authors list (link)
^ Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO (June 2011). "Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models". Pharmaceutical Research. 28 (10): 2610–27. doi:10.1007/s11095-011-0490-x. PMID 21681607.{{cite journal}}: CS1 maint: multiple names: authors list (link)

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[pmid20005103-1] Blakemore DC, Bryans JS, Carnell P, Carr CL, Chessum NE, Field MJ, Kinsella N, Osborne SA, Warren AN, Williams SC (January 2010). "Synthesis and in vivo evaluation of bicyclic gababutins". Bioorganic & Medicinal Chemistry Letters. 20 (2): 461–4. doi:10.1016/j.bmcl.2009.11.118. PMID 20005103.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[pmid19694735-2] Corrigan B, Feltner DE, Ouellet D, Werth JL, Moton AE, Gibson G (August 2009). "Effect of renal impairment on the pharmacokinetics of PD 0200390, a novel ligand for the voltage-gated calcium channel alpha-2-delta subunit". British Journal of Clinical Pharmacology. 68 (2): 174–80. doi:10.1111/j.1365-2125.2009.03444.x. PMC 2767279. PMID 19694735.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[pmid21664606-3] Quintero JE, Pomerleau F, Huettl P, Johnson KW, Offord J, Gerhardt GA (May 2011). "Methodology for rapid measures of glutamate release in rat brain slices using ceramic-based microelectrode arrays: Basic characterization and drug pharmacology". Brain Research. 1401: 1–9. doi:10.1016/j.brainres.2011.05.025. PMID 21664606.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[pmid21681607-4] Kjellsson MC, Ouellet D, Corrigan B, Karlsson MO (June 2011). "Modeling Sleep Data for a New Drug in Development using Markov Mixed-Effects Models". Pharmaceutical Research. 28 (10): 2610–27. doi:10.1007/s11095-011-0490-x. PMID 21681607.{{cite journal}}: CS1 maint: multiple names: authors list (link)

[1]

[2]

[3]

[4]

See also

References